Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Reduce” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) has received an average rating of “Reduce” from the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company.

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th.

View Our Latest Stock Analysis on BAYRY

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock opened at $5.13 on Monday. Bayer Aktiengesellschaft has a 52-week low of $4.94 and a 52-week high of $9.79. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. The firm has a fifty day moving average of $6.78 and a 200-day moving average of $7.22.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The business had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. On average, equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

About Bayer Aktiengesellschaft

(Get Free Report

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

See Also

Analyst Recommendations for Bayer Aktiengesellschaft (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.